Phosphorylated TDP-43 as a Biomarker for ALS

Phosphorylated TDP-43 in ALS

This study examined the presence of phosphorylated TDP-43 (pTDP-43) in the skin and tongue tissues of individuals with amyotrophic lateral sclerosis (ALS). While pTDP-43 is recognised as a key feature of ALS, its occurrence in peripheral tissues has not been thoroughly explored. Researchers conducted biopsies on ALS patients, healthy controls, and individuals with other neuropathies to assess pTDP-43’s potential as a biomarker.

Distinctive Patterns in Tissue Samples

The study found pTDP-43 deposits in the epidermis and dermis of ALS patients, with minimal presence in healthy controls and lower levels in those with other neuropathies. Using immunofluorescence and western blot analysis, researchers quantified pTDP-43 levels, revealing significant differences between groups. The pTDP-43/PGP ratio, which measures protein presence, increased with the clinical stage of ALS, suggesting its potential to indicate disease severity.

Clinical Implications

These findings suggest that peripheral pTDP-43 deposition could serve as a biomarker for diagnosing ALS and monitoring its progression. The study showed high diagnostic performance, with pTDP-43 measures effectively distinguishing ALS patients from healthy controls and those with other neuropathies. However, researchers stress the need for larger and longer-term studies to confirm these findings and establish pTDP-43’s role in clinical settings.